ad

Bartronics India Q1 Results FY26: Q1 PAT Falls 49.72% to ₹0.45 Crore; Revenue Down 34.91% YoY

Q1 Results FY26


25 Aug 2025 • 4:26 pm

Bartronics India Q1 Results FY26: Q1 PAT Falls 49.72% to ₹0.45 Crore; Revenue Down 34.91% YoY

Bartronics India Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

ParticularsQuarter Ended
30-06-202530-06-2024
Revenue from Operations₹8.33₹13.57
Profit Before Tax (PBT)-₹0.79₹0.28
Profit After Tax (PAT)₹0.45₹0.89

(Figures in crores)

Bartronics India Q1 Results FY26 Highlights (Q1 FY26 vs FY25)

  • Bartronics India clocked Q1 FY26 standalone revenue of ₹8.83 crores vs ₹13.57 crores. 
  • On the profit front, Bartronics India earned a standalone PAT of ₹0.45 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹0.89 crore.
  • As per the standalone figures, the quarterly PAT of Bartronics India has decreased by 49.72%, and revenue has decreased by 34.91% YoY.

Bartronics India Share Price Performance

On the opening bell of 25th August 2025, the shares of Bartronics India opened at ₹12.58 per share. However, the initial gains are wiped out as of now, and Bartronics India shares are trading at ₹12.22 per share, lower than their opening price. 

Considering the long-term performance, Bartronics India shares have yielded close to -33.60% returns in the past 1 year, and 5-year returns stand at -2.55%. Over the maximum timeframe, the Bartronics India share provided -2.55% returns to investors. 

What Analysts Expect Post Q1 Results?

As Bartronics India has posted robust Q1 results for FY26, analysts are expecting positive trends in its share price. As per the analysts, Bartronics India share price could reach ₹20.30 per share in the coming year, and in downtrends, the share price could hit the level of ₹8.00 per share. However, one must ignore the risk of volatility in the stock market and invest in Bartronics India shares after thorough research. 

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Also Read : Astrazeneca Pharma Q1 Results FY26: Q1 PAT Rises 573.54% to ₹55.83 Crore; Revenue Up 35.81% YoY

Recent Articles

Current Infraprojects IPO GMP & Review: Apply or Avoid?

Sattva Engineering Construction IPO GMP & Review: Apply or Avoid?

Anlon Healthcare IPO GMP & Review: Apply or Avoid?

Vikran Engineering IPO GMP & Review: Apply or Avoid?

ARC Insulation & Insulators IPO GMP: Day 3 IPO Live Updates

Relative Strength Index | Everything You Should Know About

PhysicsWallah IPO Details: Everything You Should Know about

Studio LSD  IPO Listing Preview: What to Expect Now?

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down